Saputo outlines dairy-protein strategy and expands buyback authorization

Saputo presented its strategy to institutional investors at the Scotiabank Back to School Conference. Mr Colizza said the Montréal-based company was moving away from lower-margin commodity cheese and towards whey fractions, specialized dairy ingredients and high-protein cultured products.

He described demand for dairy protein as a structural change rather than a temporary dietary trend. Conventional cheese volumes are growing at low single-digit rates, while whey concentrates, isolates and bio-active fractions are expanding at double-digit rates in sports nutrition, clinical feeding, adult wellness and functional foods.

Mr Colizza said total whey supply remains limited by the amount of cheese produced. That imbalance has supported premium pricing for dairy ingredients, according to the presentation. He characterized the market as being “the bottom of the third” inning of its growth cycle.

For fiscal 2027 and 2028, Saputo plans to direct capital towards functional dairy categories. The company intends to expand cultured products and cottage cheese production, including a planned 30% to 40% increase in capacity at its Friendship facility in New York. It also plans to invest in ultrafiltered and other value-added fluid-milk lines.

The processor is introducing mechanical automation and artificial-intelligence tools in supply-chain planning and processing operations. The presentation linked those measures to the company’s efforts to control manufacturing overheads and protect operating margins.

Saputo has also been simplifying its portfolio and reducing its international exposure. It has completed exits and carve-outs involving Argentina, Australia and the United Kingdom; its British operations were sold to Lactalis in a transaction valued at $1.86bn. Mr Colizza said future mergers and acquisitions would be selective, focusing on “last mile” brand access and the distribution of industrial ingredients rather than broad volume expansion.

The company said its normal course issuer bid would cover up to 6%, compared with 5% previously. Saputo presented the change alongside its investments in protein fractionation and its description of the balance sheet as under-leveraged.